Cytosorbents Corp. (CTSO)

Price$0.46

Value ScoreB

Growth ScoreD

Momentum ScoreD

Favorite Metrics

Price vs S&P 500 (26W)-51.33%

Price vs S&P 500 (4W)-24.62%

VGM Score38.29

Market Capitalization$28.82M

All Metrics

Book Value / Share (Quarterly)$0.04

P/TBV (Annual)15.00x

Indicated Dividend (Annual)$0.00

Revenue Growth (3Y)2.23%

Cash Flow / Share (Quarterly)$-0.17

Price vs S&P 500 (YTD)-36.33%

Gross Margin (TTM)71.01%

Net Profit Margin (TTM)-31.85%

EPS (TTM)$-0.19

10-Day Avg Trading Volume0.22M

EPS Excl Extra (TTM)$-0.19

Revenue Growth (5Y)-2.00%

EPS (Annual)$-0.13

ROI (Annual)-36.32%

Gross Margin (Annual)71.48%

Net Profit Margin (5Y Avg)-62.45%

Cash / Share (Quarterly)$0.08

Revenue Growth QoQ (YoY)1.57%

ROA (Last FY)-18.56%

Revenue Growth TTM (YoY)7.72%

EBITD / Share (TTM)$-0.21

ROE (5Y Avg)-116.40%

Operating Margin (TTM)-38.88%

Cash Flow / Share (Annual)$-0.20

P/B Ratio13.14x

P/B Ratio (Quarterly)16.18x

Net Income / Employee (Annual)$-63,600

EV / Revenue (TTM)1.10x

Net Interest Coverage (TTM)-2.98x

ROA (TTM)-26.55%

EPS Incl Extra (Annual)$-0.13

Current Ratio (Annual)2.13x

Quick Ratio (Quarterly)0.73x

3-Month Avg Trading Volume0.10M

52-Week Price Return-56.29%

Revenue / Employee (TTM)$288,400

Tangible BV / Share (Quarterly)$0.04

P/S Ratio (Annual)0.78x

Asset Turnover (Annual)0.84x

52-Week High$1.39

Operating Margin (5Y Avg)-63.98%

EPS Excl Extra (Annual)$-0.13

CapEx CAGR (5Y)-21.81%

Tangible BV CAGR (5Y)-48.65%

26-Week Price Return-43.40%

Quick Ratio (Annual)1.42x

13-Week Price Return-42.98%

Total Debt / Equity (Annual)2.82x

Current Ratio (Quarterly)1.09x

Enterprise Value$40.97M

Revenue / Share Growth (5Y)-10.83%

Asset Turnover (TTM)0.83x

Book Value / Share Growth (5Y)-44.79%

Revenue / Employee (Annual)$287,300

Inventory Turnover (Annual)2.64x

Pretax Margin (Annual)-23.20%

Cash / Share (Annual)$0.10

3-Month Return Std Dev62.40%

Gross Margin (5Y Avg)67.33%

Net Income / Employee (TTM)$-91,900

ROE (Last FY)-138.88%

Net Interest Coverage (Annual)-3.24x

EPS Basic Excl Extra (Annual)$-0.13

Receivables Turnover (TTM)5.02x

Total Debt / Equity (Quarterly)7.73x

EPS Incl Extra (TTM)$-0.19

Receivables Turnover (Annual)4.99x

ROI (TTM)-51.93%

P/S Ratio (TTM)0.77x

Pretax Margin (5Y Avg)-65.04%

Revenue / Share (Annual)$0.60

Tangible BV / Share (Annual)$0.04

Price vs S&P 500 (52W)-80.65%

Year-to-Date Return-28.17%

5-Day Price Return-1.90%

EPS Normalized (Annual)$-0.13

ROA (5Y Avg)-39.37%

Net Profit Margin (Annual)-22.12%

Month-to-Date Return-6.50%

Cash Flow / Share (TTM)$-0.50

EBITD / Share (Annual)$-0.23

Operating Margin (Annual)-41.30%

LT Debt / Equity (Annual)2.82x

ROI (5Y Avg)-68.38%

LT Debt / Equity (Quarterly)4.70x

EPS Basic Excl Extra (TTM)$-0.19

P/TBV (Quarterly)15.00x

P/B Ratio (Annual)6.80x

Inventory Turnover (TTM)2.88x

Pretax Margin (TTM)-32.93%

Book Value / Share (Annual)$0.09

Price vs S&P 500 (13W)-51.24%

Beta1.35x

Revenue / Share (TTM)$0.59

ROE (TTM)-165.13%

52-Week Low$0.43

vGradeB

gGradeD

mGradeD

vgmGradeD

Show chart for

Earnings Surprise History

Q1 26-0.08est. -0.06

Analyst Recommendations

Mar 2026

Apr 2026

May 2026

Jun 2026

4.00

2.17

Industry Peers — Surgical & Medical Instruments(138)

Symbol	Value Score	Growth Score	Momentum Score	Price
CTSOCytosorbents Corp.	B	D	D	$0.46
SYKStryker Corporation	C	C	C	$305.66
MMM3M Company	C	F	C	$153.76
BSXBoston Scientific Corp.	C	B	D	$48.55
MDLNMedline Inc. Class A common stock	C	D	D	$33.61
BDXBecton, Dickinson and Co.	B	C	C	$151.16
RMDResMed Inc.	C	B	C	$196.04
DXCMDexCom, Inc.	C	B	C	$72.86
WSTWest Pharmaceutical Services, Inc.	D	C	B	$314.50
SOLVSolventum Corporation	C	D	B	$81.01
PENPenumbra, Inc.	F	C	B	$320.53

About

CytoSorbents develops proprietary polymer adsorption technology to treat life-threatening conditions in intensive care and cardiac surgery. Its EU-approved flagship product, CytoSorb, functions as an extracorporeal cytokine absorber designed to reduce inflammation and prevent multiple organ failure in critical illnesses such as sepsis and trauma. The company generates revenue from product sales across Germany and the United States, supplemented by government grants, with distribution through direct sales and strategic partnerships.